Table 1.

EORTC phase III 40983 study of perioperative FOLFOX4: Progression-free survival.

	No. pts CT	No. pts Surgery	% Absolute Difference in 3-yr PFS	HR (CI)	P Value
All patients	182	182	+7.2% (28.1% to 35.4%)	0.79 (0.62–1.02)	P = .058
All eligible	171	171	+8.1% (28.1% to 36.2%)	0.77 (0.60–1.00)	P = .041
All resected	151	152	+9.2% (33.2% to 42.4%)	0.73 (0.55–0.97)	P = .025

Abbreviations: CI = confidence interval; CT = perioperative chemotherapy; EORTC = European Organisation for the Research and Treatment of Cancer; FOLFOX4 = 5-fluorouracil, leucovorin, oxaliplatin; HR = hazard ratio; PFS = progression-free survival.

Data from Nordlinger et al.⁵²